Ornipressin
 | |
| Names | |
|---|---|
| IUPAC name
(2S)-N-[(2S)-5-Amino-1-[(2-amino-2-oxoethyl)amino]- 1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)- 19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl] -6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17- pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide | |
| Identifiers | |
| ATC code | H01 |
3397-23-7  | |
| ChemSpider | 16736525 |
| |
| Jmol-3D images | Image |
| MeSH | Ornipressin |
| PubChem | 14257660 |
| |
| Properties | |
| C45H63N13O12S2 | |
| Molar mass | 1042.19 g/mol |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
verify (what is: / ?) | |
| Infobox references | |
Ornipressin is a vasoconstrictor,[1][2] haemostatic and renal agent.
References
- ↑ H. Fruhstofer, M.D., M. Heisler, M.D. (1994). "Dose-response relation of ornipressin with regard to vasoconstriction in human skin". Br. J. Anaesth. 73 (2): 220–224. doi:10.1093/bja/73.2.220.
- ↑ Marc De Kock, MD, Pierre-Francois Laterre, MD, Patricia Andruetto, MD, Lionel Vanderessen, MD, Sylvie Dekrom, MD, Bernard Vanderick, MD and Patricia Lavand’homme, MD (June 2000). "Ornipressin (Por 8): An Efficient Alternative to Counteract Hypotension During Combined General/Epidural Anesthesia". Anesthesia & Analgesia 90 (6): 1301–1307. doi:10.1097/00000539-200006000-00008.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||